Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
15.50
+0.10 (0.65%)
Sep 18, 2024, 4:00 PM EDT - Market closed
Immunome Revenue
Immunome had revenue of $2.36M in the quarter ending June 30, 2024, a decrease of -44.55%. This brings the company's revenue in the last twelve months to $10.78M, up 62.73% year-over-year. In the year 2023, Immunome had annual revenue of $14.02M.
Revenue (ttm)
$10.78M
Revenue Growth
+62.73%
P/S Ratio
59.82
Revenue / Employee
$196,073
Employees
55
Market Cap
930.84M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pediatrix Medical Group | 2.00B |
PetIQ | 1.13B |
Embecta | 1.12B |
MiMedx Group | 340.46M |
GeneDx Holdings | 243.66M |
Aurinia Pharmaceuticals | 207.11M |
Perspective Therapeutics | 1.46M |
IMNM News
- 5 days ago - Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 - Business Wire
- 20 days ago - Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference - Business Wire
- 5 weeks ago - Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 7 weeks ago - Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities - Business Wire
- 2 months ago - Immunome: AL102 And Other Established Protein Targets Could Drive Value - Seeking Alpha
- 2 months ago - Immunome Appoints Phil Tsai as Chief Technical Officer - Business Wire
- 4 months ago - Immunome Announces Completion of Purchase of Assets from Atreca - Business Wire
- 4 months ago - Immunome Announces Promotion of Max Rosett to Chief Financial Officer - Business Wire